v3.25.2
Segment Reporting
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 15. Segment Reporting

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy AIkido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Dominari Labs (formerly Aikido Labs), which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido.

 

The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.”

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.

 

   Three Months Ended June 30, 2025 
   Dominari
Financial		   Legacy
AIkido
Pharma		   Consolidated 
Revenue  $34,095   $
-
   $34,095 
Operating Costs               
Compensation and benefits   30,540    19,752    50,292 
Professional and consulting fees   711    495    1,206 
Data processing   177    
-
    177 
Other (income)/expenses   (742)   2,588    1,846 
Loss from operations   3,409    (22,835)   (19,426)
                
Other (expenses) income               
Interest income   364    
-
    364 
Gain on marketable securities   4,236    806    5,042 
Change in fair value of investments   
-
    31,680    31,680 
Total other (expenses) income   4,600    32,486    37,086 
Net gain  $8,009   $9,651   $17,660 
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   6,959    9,651    16,610 
Total assets   44,976    63,312    108,288 

 

   Six Months Ended June 30, 2025 
   Dominari   Legacy
AIkido		     
   Financial   Pharma   Consolidated 
Revenue  $42,206   $
-
   $42,206 
Operating Costs               
Compensation and benefits   37,430    48,557    85,987 
Professional and consulting fees   1,358    1,269    2,627 
Data processing   359    
-
    359 
Other expenses   733    3,936    4,669 
Loss from operations   2,326    (53,762)   (51,436)
                
Other (expenses) income               
Interest income   381    42    423 
Gain on marketable securities   3,326    638    3,964 
Unrealized loss on note receivable   
-
    221    221 
Change in fair value of investments   
-
    32,000    32,000 
Total other (expenses) income   3,707    32,901    36,608 
Net loss  $6,033   $(20,861)  $(14,828)
Noncontrolling interests   1,050    
-
    1,050 
Net gain attributable to common stock holders of Dominari Holdings   4,983    (20,861)   (15,878)
Total assets   44,976    63,312    108,288 
   Three Months Ended June 30, 2024 
   Dominari Financial   Legacy AIkido Pharma   Consolidated 
Revenue  $5,503   $671   $6,174 
Operating Costs               
Compensation and benefits   4,962    1,725    6,687 
Professional and consulting fees   293    168    461 
Data processing   227    12    239 
Other expenses   847    676    1,523 
Loss from operations   (826)   (1,910)   (2,736)
                
Other (expenses) income               
Interest income   205    80    285 
Gain on marketable securities   
-
    104    104 
Unrealized loss on note receivable   
-
    (742)   (742)
Change in fair value of investments   
-
    (3,031)   (3,031)
Total other (expenses) income   205    (3,589)   (3,384)
Net loss  $(621)  $(5,499)  $(6,120)
Total assets   17,361    31,712    49,073 

 

   Six Months Ended June 30, 2024 
   Dominari
Financial		   Legacy
AIkido
Pharma		   Consolidated 
Revenue  $6,870   $671   $7,541 
Operating Costs               
Compensation and benefits   6,384    2,452    8,836 
Professional and consulting fees   761    657    1,418 
Data processing   375    45    420 
Other expenses   1,370    1,038    2,408 
Loss from operations   (2,020)   (3,521)   (5,541)
                
Other (expenses) income               
Interest income   341    108    449 
Gain on marketable securities   
-
    678    678 
Unrealized loss on note receivable   
-
    (1,657)   (1,657)
Change in fair value of investments   
-
    (5,490)   (5,490)
Total other (expenses) income   341    (6,361)   (6,020)
Net loss  $(1,679)  $(9,882)  $(11,561)
Total assets   17,361    31,712    49,073